The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes
- PMID: 16433709
- DOI: 10.1111/j.1464-5491.2005.01755.x
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes
Abstract
Aims: In treating Type 2 diabetes (T2DM), UK guidelines recommend metformin in obese and overweight patients, and either sulphonylureas or metformin in normal weight patients. Although other factors influence prescribing choice, a key objective in treating T2DM is to lower plasma glucose. There is little data on how glycaemic response to oral agents varies with body mass index (BMI). Therefore, we assessed current prescribing practice and effect of BMI on glycaemic response to sulphonylureas and metformin in a large population T2DM cohort.
Methods: BMI was determined in 3856 T2DM patients on sulphonylurea or metformin monotherapy in 2001-2002. Patients were identified from the Diabetes Audit and Research in Tayside, Scotland (DARTS) database. In a linear regression, the effect of BMI and other confounders on drug response was assessed in 2064 treatment-naïve patients commencing sulphonylureas or metformin between 1994 and 2002.
Results: In 2001-2002, metformin was more likely to be used in obese than non-obese patients: 13% normal weight, 33.6% overweight and 62.1% obese patients were treated with metformin. Glycaemic response to sulphonylureas was not influenced by BMI (P = 0.81). Metformin was more effective in lowering glucose in those with a lower BMI (r = -0.02, P = 0.02), although the clinical impact of this was small. The HbA(1c) reduction in non-obese patients was similar to that in obese patients (1.46% vs. 1.34%, P = 0.11).
Conclusions: Glycaemic response to metformin in non-obese and obese patients is similar, suggesting that an individual's BMI should not influence the choice of oral agent. Given the non-glycaemia-related benefits of metformin, it should be used in more non-obese patients than is current practice in Tayside, Scotland.
Similar articles
-
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.Curr Med Res Opin. 2009 Mar;25(3):607-15. doi: 10.1185/03007990802711024. Curr Med Res Opin. 2009. PMID: 19232035 Clinical Trial.
-
Rosiglitazone RECORD study: glucose control outcomes at 18 months.Diabet Med. 2007 Jun;24(6):626-34. doi: 10.1111/j.1464-5491.2007.02160.x. Diabet Med. 2007. PMID: 17517066 Free PMC article. Clinical Trial.
-
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.Diabet Med. 2007 Apr;24(4):350-8. doi: 10.1111/j.1464-5491.2007.02078.x. Epub 2007 Feb 28. Diabet Med. 2007. PMID: 17335466
-
Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005. Drugs. 2005. PMID: 15669880 Review.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
Sex differences in energy metabolism: natural selection, mechanisms and consequences.Nat Rev Nephrol. 2024 Jan;20(1):56-69. doi: 10.1038/s41581-023-00781-2. Epub 2023 Nov 3. Nat Rev Nephrol. 2024. PMID: 37923858 Review.
-
Effects of KISS1 structural polymorphism on the risk of polycystic ovary syndrome and reproductive hormones in Iraqi women who take metformin.J Int Med Res. 2023 Sep;51(9):3000605231196837. doi: 10.1177/03000605231196837. J Int Med Res. 2023. PMID: 37702549 Free PMC article.
-
Association of Met420del Variant of Metformin Transporter Gene SLC22A1 with Metformin Treatment Response in Ethiopian Patients with Type 2 Diabetes.Diabetes Metab Syndr Obes. 2023 Aug 23;16:2523-2535. doi: 10.2147/DMSO.S426632. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 37641646 Free PMC article.
-
Predictors of Metformin Failure: Repurposing Electronic Health Record Data to Identify High-Risk Patients.J Clin Endocrinol Metab. 2023 Jun 16;108(7):1740-1746. doi: 10.1210/clinem/dgac759. J Clin Endocrinol Metab. 2023. PMID: 36617249 Free PMC article.
-
Association of SLC22A1, SLC22A2, SLC47A1, and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients.Biomedicines. 2022 Oct 12;10(10):2546. doi: 10.3390/biomedicines10102546. Biomedicines. 2022. PMID: 36289808 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous